# Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

> **NCT00517712** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Christian Medical College, Vellore, India** · enrollment: 400 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Single agent arsenic trioxide

## Key facts

- **NCT ID:** NCT00517712
- **Lead sponsor:** Christian Medical College, Vellore, India
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2009-07
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2007-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517712, "Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00517712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*